Shots:

• The positive opinion recommendation follows the study assessing arginine and lysine of same content as LysaKare- evaluating its safety and efficacy
• The EC will review CHMP’s opinion with its expected results within three months- if approved will be a novel solution of this concentration available in EU  
• LysaKare 25g/25g is a solution to reduce kidney exposure during PRRT with Lutathera (lutetium (¹⁷⁷Lu) oxodotreotide) in adults. Lutathera is indicated to treat unresectable or metastatic- progressive- well differentiated (G1 and G2)- somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults and is approved as PPRT in EU in Sep 2017

Ref: Novartis | Image: Twitter